Home > Oncology > ASCO 2020 > Gastrointestinal Cancer > Perioperative chemotherapy for resectable pancreatic ductal adenocarcinoma

Perioperative chemotherapy for resectable pancreatic ductal adenocarcinoma

Expert
Prof. Davendra Sohal, University of Cincinnati, OH, USA
Conference
ASCO 2020
Trial
Phase 2, SWOG S1505
The phase 2 SWOG S1505 study, evaluating the efficacy and safety of 2 perioperative chemotherapy regimens, failed to reach its primary endpoint as overall survival (OS) at 2 years did not exceed the prespecified threshold. Dissection followed by adjuvant chemotherapy remains the standard-of-care for resectable pancreatic cancer. However, outcomes remain suboptimal, due to the inability of many patients to receive adjuvant chemotherapy as well as early progression in the perioperative period. Perioperative chemotherapy using aggressive multi-agent chemotherapy regimens for early control of systemic disease could overcome these problems. Key eligibility criteria for SWOG S1505, designed to evaluate efficacy and safety of both modified FOLFIRINOX and gemcitabine plus nab-paclitaxel, included a confirmed tissue diagnosis of pancreatic adenocarcinoma [1]. No prior cancer therapy of any kind was allowed. Resectability was strictly defined, using a contras...


Please login to read the full text of the article.


If you have no account yet, please register now.





Posted on